Advertisement
Research Article

Use of a Bacteriophage Lysin to Identify a Novel Target for Antimicrobial Development

  • Raymond Schuch mail,

    rschuch@contrafect.com

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    Current address: ContraFect Corporation, Yonkers, New York, United States of America

    X
  • Adam J. Pelzek,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Assaf Raz,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Chad W. Euler,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Patricia A. Ryan,

    Affiliations: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America, Hunter College School of Health Sciences, New York, New York, United States of America

    X
  • Benjamin Y. Winer,

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Andrew Farnsworth,

    Affiliation: Information Science Program, Cornell Lab of Ornithology, Ithaca, New York, United States of America

    X
  • Shyam S. Bhaskaran,

    Affiliation: Laboratory of Structural Microbiology, The Rockefeller University, New York, New York, United States of America

    X
  • C. Erec Stebbins,

    Affiliation: Laboratory of Structural Microbiology, The Rockefeller University, New York, New York, United States of America

    X
  • Yong Xu,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    X
  • Adrienne Clifford,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    X
  • David J. Bearss,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    Current address: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America

    X
  • Hariprasad Vankayalapati,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    Current address: Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America

    X
  • Allan R. Goldberg,

    Affiliation: Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

    Current address: Avacyn Pharmaceuticals, Inc., Teaneck, New Jersey, United States of America

    X
  • Vincent A. Fischetti

    Affiliation: Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America

    X
  • Published: April 10, 2013
  • DOI: 10.1371/journal.pone.0060754

About the Authors

Raymond Schuch, Adam J. Pelzek, Assaf Raz, Chad W. Euler, Patricia A. Ryan, Benjamin Y. Winer, Vincent A. Fischetti
Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, New York, United States of America
Patricia A. Ryan
Hunter College School of Health Sciences, New York, New York, United States of America
Andrew Farnsworth
Information Science Program, Cornell Lab of Ornithology, Ithaca, New York, United States of America
Shyam S. Bhaskaran, C. Erec Stebbins
Laboratory of Structural Microbiology, The Rockefeller University, New York, New York, United States of America
Yong Xu, Adrienne Clifford, David J. Bearss, Hariprasad Vankayalapati, Allan R. Goldberg
Astex Pharmaceuticals, Inc. (formerly known as SuperGen, Inc.), Dublin, California, United States of America

Corresponding Author

Email: rschuch@contrafect.com

Competing Interests

The authors have the following interests: Raymond Schuch is a PLOS ONE Editorial Board member. Yong Xu, Adrianne Clifford, David J. Bearss and Hariprasad Vankayalapati are employed by, and Allan R. Goldberg is a Board Member of, Astex Pharmaceuticals Inc. (formerly known as SuperGen, Inc.). Pending patent "Oxo-Imidazolyl Compounds," number US 2009/0298900 A1 and one provisional application. There are no further products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.

Author Contributions

Conceived and designed the experiments: RS AJP AR CWE PAR CES ARG VAF. Performed the experiments: RS AJP AR CWE BYW SSB YX AC HV. Analyzed the data: RS AJP AR CWE PAR BYW AF CES SSB YX AC DJB HV ARG VAF. Contributed reagents/materials/analysis tools: RS PAR AF DJB ARG VAF. Wrote the paper: RS.